Opinion

Video

Insights From ARANOTE and Clinical Practice

Key Takeaways

  • The ARANOTE trial enables personalized cancer treatment, allowing oncologists to tailor therapy based on individual patient needs and clinical situations.
  • Flexibility in the trial design accommodates varying patient profiles, optimizing treatment outcomes and enhancing therapeutic decision-making.
SHOW MORE

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how the ARANOTE trial results support using darolutamide plus androgen deprivation therapy in a broad range of patients with metastatic hormone-sensitive prostate cancer, offering flexibility in treatment choices by providing an effective non-chemotherapy option that can be tailored to individual patient needs and preferences.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
© 2025 MJH Life Sciences

All rights reserved.